1.	REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Phase: Phase III Type: Diagnostic Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: WX/20-002, NCT01762592
2.	Phase II Pilot Study of Neoadjuvant Sunitinib Malate Followed by Cytoreductive Nephrectomy and Adjuvant Sunitinib Malate in Patients With Stage IV Renal Cell Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UPCC-10807, UPCC 10807, PFIZER-807184, NCT00717587
3.	Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Phase: No phase specified Type: Diagnostic Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-134, NCT01582204